{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:25:25Z","timestamp":1791962725704,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.leukres.2021.106523","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T18:59:06Z","timestamp":1612637946000},"page":"106523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-2385","authenticated-orcid":false,"given":"Tulin","family":"Ozkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalda","family":"Hekmatshoar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-0359","authenticated-orcid":false,"given":"Arzu Zeynep","family":"Karabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Altinok Gunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur","family":"Karadag Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuman","family":"Sunguroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106523_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2021.106523_bib0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood.V79.4.1029.bloodjournal7941029","article-title":"Clonal development and karyotype evolution during leukemogenesis of BCR\/ABL transgenic mice","volume":"79","author":"Voncken","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106523_bib0015","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1038\/bcj.2012.30","article-title":"Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy","volume":"2","author":"Deangelo","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2021.106523_bib0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.clml.2018.06.029","article-title":"Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors","volume":"18","author":"Chopade","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2021.106523_bib0025","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2021.106523_bib0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14715\/cmb\/2018.64.6.5","article-title":"Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms","volume":"64","author":"Hekmatshoar","year":"2018","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.leukres.2021.106523_bib0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/TCRM.S1527","article-title":"Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark)","volume":"4","author":"Henkes","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.leukres.2021.106523_bib0040","article-title":"Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias","volume":"9","author":"Kang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2021.106523_bib0045","first-page":"3723","article-title":"Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB\/c mice","volume":"24","author":"Ohara","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.leukres.2021.106523_bib0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00210-016-1337-0","article-title":"Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic\/extrinsic apoptotic pathways in rat hepatocellular carcinoma model","volume":"390","author":"Abdel-Hamid","year":"2017","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.leukres.2021.106523_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2008.03.047","article-title":"Anti-tumor activity of N-thiolated beta-lactam antibiotics","volume":"268","author":"Chen","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2021.106523_bib0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejphar.2003.11.035","article-title":"Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats","volume":"484","author":"Asakura","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.leukres.2021.106523_bib0065","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.18632\/oncotarget.3174","article-title":"Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2021.106523_bib0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3332\/ecancer.2015.513","article-title":"Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent","volume":"9","author":"Van Nuffel","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.leukres.2021.106523_bib0075","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1038\/bcj.2016.32","article-title":"Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels","volume":"6","author":"Pillozzi","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2021.106523_bib0080","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.bbmt.2018.12.097","article-title":"The effect of azithromycin on relapse in patients with moderate-severe chronic graft versus host disease (CGVHD)","volume":"25","author":"Shamoun","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2021.106523_bib0085","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.18632\/aging.101905","article-title":"Doxycycline, Azithromycin and Vitamin C (DAV): a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)","volume":"11","author":"Fiorillo","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.leukres.2021.106523_bib0090","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2174\/1871520618666171229222534","article-title":"Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells","volume":"18","author":"Ozkan","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.leukres.2021.106523_bib0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbi.2016.11.013","article-title":"Optically active stereoisomers of 5-(1-iodoethyl)-4-(4\u2019-isopropylphenyl)dihydrofuran-2-one: The effect of the configuration of stereocenters on apoptosis induction in canine cancer cell lines","volume":"261","author":"Pawlak","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.leukres.2021.106523_bib0100","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ijc.25394","article-title":"Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma","volume":"128","author":"Gwak","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2021.106523_bib0105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0014-4827(88)90419-3","article-title":"The membrane transport system responsible for multidrug resistance is operating in nonresistant cells","volume":"178","author":"Neyfakh","year":"1988","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.leukres.2021.106523_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071123","article-title":"Methylsulfonylmethane Induces p53 Independent Apoptosis in HCT-116 Colon Cancer Cells","volume":"17","author":"Karabay","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2021.106523_bib0115","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1126\/science.281.5381.1312","article-title":"Caspases: enemies within","volume":"281","author":"Thornberry","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.leukres.2021.106523_bib0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00011-013-0590-7","article-title":"NF-kappaB RNAi decreases the Bax\/Bcl-2 ratio and inhibits TNF-alpha-induced apoptosis in human alveolar epithelial cells","volume":"62","author":"Li","year":"2013","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.leukres.2021.106523_bib0125","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1080\/10428194.2016.1256479","article-title":"Imatinib resistance in chronic myeloid leukemia due to a rare mutation","volume":"58","author":"Balasubramanian","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106523_bib0130","doi-asserted-by":"crossref","first-page":"18204","DOI":"10.18632\/oncotarget.7569","article-title":"Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies","volume":"7","author":"Salizzato","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2021.106523_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111748","article-title":"Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators","volume":"185","author":"Schoepf","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.leukres.2021.106523_bib0140","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3109\/10428194.2012.656105","article-title":"Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia","volume":"53","author":"Carella","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106523_bib0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.18620\/ctt-1866-8836-2019-8-1-12-19","article-title":"Drug repurposing in leukemia treatment and hematopoietic stem cell transplantation","volume":"8","author":"Chukhlovin","year":"2019","journal-title":"Cell. Ther. Transpl."},{"key":"10.1016\/j.leukres.2021.106523_bib0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FPC.0000000000000270","article-title":"PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.leukres.2021.106523_bib0155","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/cancers4041318","article-title":"Azithromycin synergistically enhances anti-proliferative activity of vincristine in cervical and gastric cancer cells","volume":"4","author":"Zhou","year":"2012","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2021.106523_bib0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12964-019-0408-5","article-title":"Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo","volume":"17","author":"Zhang","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.leukres.2021.106523_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172371","article-title":"Expression and activity of multidrug resistance proteins in mature endothelial cells and their precursors: a challenging correlation","volume":"12","author":"Krawczenko","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2021.106523_bib0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1008255725515","article-title":"No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer","volume":"9","author":"Hegewisch-Becker","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2021.106523_bib0175","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10408369509084685","article-title":"P-glycoprotein: clinical significance and methods of analysis","volume":"32","author":"van der Heyden","year":"1995","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.leukres.2021.106523_bib0180","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V86.6.2329.bloodjournal8662329","article-title":"Correlation of multidrug resistance (MDR1) protein expression with functional dye\/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-\/efflux+ and MDR1+\/efflux- cases","volume":"86","author":"Leith","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106523_bib0185","article-title":"Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin","volume":"22","author":"Tanaka","year":"2020","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.leukres.2021.106523_bib0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12943-019-1030-2","article-title":"Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy","volume":"18","author":"Chen","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.leukres.2021.106523_bib0195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2009.11.055","article-title":"Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation","volume":"391","author":"Ohtomo","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.leukres.2021.106523_bib0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1080\/15384101.2018.1515551","article-title":"A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX","volume":"17","author":"Sotgia","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2021.106523_bib0205","doi-asserted-by":"crossref","first-page":"30472","DOI":"10.18632\/oncotarget.5401","article-title":"High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant","volume":"6","author":"Farnie","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2021.106523_bib0210","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.18632\/oncotarget.4401","article-title":"Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells","volume":"6","author":"De Luca","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2021.106523_bib0215","doi-asserted-by":"crossref","first-page":"11029","DOI":"10.18632\/oncotarget.2789","article-title":"Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1\/2 inhibition","volume":"5","author":"Lamb","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2021.106523_bib0220","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics8030110","article-title":"Mitochondrial toxicity of azithromycin results in aerobic glycolysis and DNA damage of human mammary epithelia and fibroblasts","volume":"8","author":"Jiang","year":"2019","journal-title":"Antibiotics"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:44Z","timestamp":1758934844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":44,"alternative-id":["S0145212621000242"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106523","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106523"}}